Ezetimibe therapy: mechanism of action and clinical update

References

• KannelWBCastelliWPGordonTCholesterol in the prediction of atherosclerotic diseaseAn Intern Med1979908591
   PubMed Web of Science ®Google Scholar
• KeysAMenottiAAravanisCThe seven countries study: 2,289 deaths in 15 yearsPrev Med1984131411546739443
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• [No authors listed]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• SacksFMPfefferMAMoyeLAThe effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigatorsN Engl J Med1996335100110098801446
   PubMed Web of Science ®Google Scholar
• ShepherdJCobbeSMFordIPrevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study GroupN Engl J Med1995333130113077566020
   PubMed Web of Science ®Google Scholar
• DownsJRClearfieldMWeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPSJAMA1998279161516229613910
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation20021063143342112485966
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med20053521425143515755765
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med20043501495150415007110
   PubMed Web of Science ®Google Scholar
• CannonCPSteinbergBAMurphySAMegaJLBraunwaldEMetaanalysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapyJ Am Coll Cardiol20064843844516875966
   PubMed Web of Science ®Google Scholar
• GrundySMCleemanJIMerzCNImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III GuidelinesJ Am Coll Cardiol20044472073215358046
   PubMed Web of Science ®Google Scholar
• CatapanoALPerspectives on low-density lipoprotein cholesterol goal achievementCurr Med Res Opin20092543144719192988
   PubMed Web of Science ®Google Scholar
• PearsonTALauroraIChuHKafonekSThe lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goalsArch Intern Med200016045946710695686
   PubMed Web of Science ®Google Scholar
• WatersDDBrotonsCChiangCWLipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goalsCirculation2009120283419546386
   PubMed Web of Science ®Google Scholar
• TaylorAJSullenbergerLELeeHJLeeJKGraceKAArterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statinsCirculation20041103512351715537681
   PubMed Web of Science ®Google Scholar
• KasteleinJJPAkdimFStroesESGSimvastatin with or without ezetimibe in familial hypercholesterolemiaNew Engl J Med20083581431144318376000
   PubMed Web of Science ®Google Scholar
• BrownBGZhaoXQChaitASimvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary diseaseN Engl J Med20013451583159211757504
   PubMed Web of Science ®Google Scholar
• BrownGAlbersJJFisherLDRegression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein BN Engl J Med1990323128912982215615
   PubMed Web of Science ®Google Scholar
• BuchwaldHVarcoRLMattsJPEffect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH)N Engl J Med19903239469552205799
   PubMed Web of Science ®Google Scholar
• RobinsonJGWangSSmithBJJacobsonTAMeta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease riskJ Am Coll Cardiol20095331632219161879
   PubMed Web of Science ®Google Scholar
• TothPPDavidsonMHCholesterol absorption blockade with ezetimibeCurr Drug Targets Cardiovasc Haematol Disord2005545546216503865
   PubMedGoogle Scholar
• BrownBGTaylorAJDoes ENHANCE diminish confidence in lowering LDL or in ezetimibe?New Engl J Med20083581504150718376002
   PubMed Web of Science ®Google Scholar
• BaysHEzetimibeExpert Opin Investig Drugs20021115871604
   PubMed Web of Science ®Google Scholar
• BurnettJRHuffMWCholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemiaExpert Opin Investig Drugs20061513371351
   PubMed Web of Science ®Google Scholar
• HuffMWBurnettJR3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretionCurr Opin Lipidol199781381459211061
   PubMed Web of Science ®Google Scholar
• IkonenEMechanisms for cellular cholesterol transport: defects and human diseasePhysiol Rev2006861237126117015489
   PubMed Web of Science ®Google Scholar
• DietschyJMTurleySDSpadyDKRole of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humansJ Lipid Res199334163716598245716
   PubMed Web of Science ®Google Scholar
• LewisGFRaderDJNew insights into the regulation of HDL metabolism and reverse cholesterol transportCirc Res2005961221123215976321
   PubMed Web of Science ®Google Scholar
• BarterPRyeKACholesteryl ester transfer protein: its role in plasma lipid transportClin Exp Pharmacol Physiol1994216636727820946
   PubMed Web of Science ®Google Scholar
• KruitJKGroenAKvan BerkelTJKuipersFEmerging roles of the intestine in control of cholesterol metabolismWorld J Gastroenterol2006126429643917072974
   PubMed Web of Science ®Google Scholar
• DavisHRJrBassoFHoosLMTetzloffGLallySMAltmannSWCholesterol homeostasis by the intestine: lessons from Niemann-Pick C1 Like 1 [NPC1L1)Atheroscler Suppl20089778118585981
   PubMed Web of Science ®Google Scholar
• IqbalJHussainMMIntestinal lipid absorptionAm J Physiol Endocrinol Metab2009296E1183E119419158321
   PubMed Web of Science ®Google Scholar
• YuLLi-HawkinsJHammerREOverexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterolJ Clin Invest200211067168012208868
   PubMed Web of Science ®Google Scholar
• LeeMHLuKPatelSBGenetic basis of sitosterolemiaCurr Opin Lipidol20011214114911264985
   PubMed Web of Science ®Google Scholar
• SalenGPatelSBattaAKSitosterolemiaCardiovasc Drug Rev20022025527012481199
   PubMed Web of Science ®Google Scholar
• AltmannSWDavisHRJrZhuLJNiemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorptionScience20043031201120414976318
   PubMed Web of Science ®Google Scholar
• RadhakrishnanASunLPKwonHJBrownMSGoldsteinJLDirect binding of cholesterol to the purified membrane region of SCAP: mechanism for a sterol-sensing domainMol Cell20041525926815260976
   PubMed Web of Science ®Google Scholar
• WeinglassABKohlerMSchulteUExtracellular loop C of NPC1L1 is important for binding to ezetimibeProc Natl Acad Sci U S A2008105111401114518682566
   PubMed Web of Science ®Google Scholar
• PearseBMSmithCJOwenDJClathrin coat construction in endocytosisCurr Opin Struct Biol20001022022810753805
   PubMed Web of Science ®Google Scholar
• GeLWangJQiWThe cholesterol absorption inhibitor ezetimibe acts by blocking the sterol-induced internalization of NPC1L1Cell Metab2008750851918522832
   PubMed Web of Science ®Google Scholar
• SantosaSVaradyKAAbuMweisSJonesPJHPhysiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist?Life Sci20078050551417113605
   PubMed Web of Science ®Google Scholar
• BaysHSteinEAPharmacotherapy for dyslipidaemia – current therapies and future agentsExpert Opin Pharmacother200341901193814596646
   PubMed Web of Science ®Google Scholar
• CatapanoALThe pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balanceFundam Clin Pharmacol200721Suppl 2212618001316
   PubMed Web of Science ®Google Scholar
• RosenblumSBHuynhTAfonsoADiscovery of 1-(4- fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)- (4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorptionJ Med Chem1998419739809526571
   PubMed Web of Science ®Google Scholar
• DavisHRJrTershakovecAMTomassiniJEMuslinerTIntestinal sterol transporters and cholesterol absorption inhibitionCurr Opin Lipidol20112246747822101558
   PubMed Web of Science ®Google Scholar
• KramerWGirbigFCorsieroDAminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membraneJ Biol Chem20052801306132015494415
   PubMed Web of Science ®Google Scholar
• SmartEJDe RoseRAFarberSAAnnexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transportProc Natl Acad Sci U S A20041013450345514985510
   PubMed Web of Science ®Google Scholar
• TemelRETangWMaYHepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibeJ Clin Invest20071171968197817571164
   PubMed Web of Science ®Google Scholar
• GhosalAHapangamaNYuanYIdentification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia)Drug Metab Dispos20043231432014977865
   PubMed Web of Science ®Google Scholar
• van HeekMFarleyCComptonDSComparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663Br J Pharmacol20001291748175410780982
   PubMed Web of Science ®Google Scholar
• JeuLChengJWMPharmacology and therapeutics of ezetimibe (SCH 58235), a cholesterol-absorption inhibitorClin Ther2003252352238714604738
   PubMed Web of Science ®Google Scholar
• Garcia-CalvoMLisnockJBullHGThe target of ezetimibe is Niemann- Pick C1-Like 1 (NPC1L1)Proc Natl Acad Sci U S A20051028132813715928087
   PubMed Web of Science ®Google Scholar
• van HeekMComptonDSDavisHRThe cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeysEur J Pharmacol2001415798411245855
   PubMed Web of Science ®Google Scholar
• RepaJJTurleySDQuanGDietschyJMDelineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorptionJ Lipid Res20054677978915654122
   PubMed Web of Science ®Google Scholar
• DietrichTHuckoTBourayouRHigh resolution magnetic resonance imaging in atherosclerotic mice treated with ezetimibeInt J Cardiovasc Imaging20092582783619662512
   PubMed Web of Science ®Google Scholar
• DavisHRJrPulaKKAltonKBBurrierREWatkinsRWThe synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitors in dogsMetab Clin Exp2001501234124111586500
   PubMed Web of Science ®Google Scholar
• LioudakiEGanotakisESMikhailidisDPEzetimibe; more than a low density lipoprotein cholesterol lowering drug? An update after 4 yearsCurr Vasc Pharmacol20119628621044019
   PubMed Web of Science ®Google Scholar
• SimonJSKarnoubMCDevlinDJSequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatmentGenomics20058664865616297596
   PubMed Web of Science ®Google Scholar
• CohenJCPertsemlidisAFahmiSMultiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levelsProc Natl Acad Sci U S A20061031810181516449388
   PubMed Web of Science ®Google Scholar
• GuytonJRCombination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy?Curr Opin Lipidol20102137237720625257
   PubMed Web of Science ®Google Scholar
• GaziIFDaskalopoulouSSNairDRMikhailidisDPEffect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statinCurr Med Res Opin20072392183219217692154
   PubMed Web of Science ®Google Scholar
• PandorAAraRMTumurIEzetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trialsJ Intern Med200926556858019141093
   PubMed Web of Science ®Google Scholar
• GagnéCBaysHEWeissSREfficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemiaAm J Cardiol2002901084109112423708
   PubMed Web of Science ®Google Scholar
• BaigentCLandrayMJReithCThe effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialLancet20113772181219221663949
   PubMed Web of Science ®Google Scholar
• MorroneDWeintraubWSTothPPLipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trialsAtherosclerosis Epub February 16, 2012
   Web of Science ®Google Scholar
• Hamilton-CraigIKostnerKColquhounDWoodhouseSCombination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemiaVasc Health Risk Manag201061023103721127699
   PubMedGoogle Scholar
• SoutarAKNaoumovaRPMechanisms of disease: genetic causes of familial hypercholesterolemiaNat Clin Pract Cardiovasc Med2007421422517380167
   PubMedGoogle Scholar
• NaoumovaRPThompsonGRSoutarAKCurrent management of severe homozygous hypercholesterolaemiasCurr Opin Lipidol20041541342215243214
   PubMed Web of Science ®Google Scholar
• PitsavosCSkoumasITousoulisDThe impact of ezetimibe and high-dose of statin treatment on LDL levels in patients with heterozygous familial hypercholesterolemiaInt J Cardiol200913428028118353459
   PubMed Web of Science ®Google Scholar
• SalenGvon BergmannKLütjohannDEzetimibe effectively reduces plasma plant sterols in patients with sitosterolemiaCirculation200410996697114769702
   PubMed Web of Science ®Google Scholar
• Tsubakio-YamamotoKNishidaMNakagawa-ToyamaYMasudaDOhamaTYamashitaSCurrent therapy for patients with sitosterolemia – effect of ezetimibe on plant sterol metabolismJ Atheroscler Thromb20101789190020543520
   PubMed Web of Science ®Google Scholar
• LütjohannDvon BergmannKSirahWLong-term efficacy and safety of ezetimibe 10 mg in patients with homozygous sitosterolemia: a 2-year, open-label extension studyInt J Clin Pract2008621499151018822021
   PubMed Web of Science ®Google Scholar
• SudhopTLütjohannDReberDInhibition of intestinal cholesterol absorption and endogenous cholesterol synthesis by ezetimibe/ simvastatin in humansJ Am Coll Cardiol200545392A
   Web of Science ®Google Scholar
• RobinsonJGBallantyneCMGrundySMLipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study)Am J Cardiol20091031694170219539078
   PubMed Web of Science ®Google Scholar
• GoldbergRBGuytonJRMazzoneTEzetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL studyMayo Clin Proc2006811579158817165637
   PubMed Web of Science ®Google Scholar
• WinklerKJacobSMüller-ScheweTHoffmannMMKonradTEzetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitusAtherosclerosis201222018919322115011
   PubMed Web of Science ®Google Scholar
• KotaniKSakaneNTaniguchiNEffect of ezetimibe on remnant-like particle cholesterol in subjects with metabolic syndromeMed Princ Pract20122113413822024552
   PubMed Web of Science ®Google Scholar
• Tota-MaharajRDefilippisAPBlumenthalRSBlahaMJA practical approach to the metabolic syndrome: review of current concepts and managementCurr Opin Cardiol20102550251220644468
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• GuytonJRBaysHESafety considerations with niacin therapyAm J Cardiol20079922C31C
   PubMed Web of Science ®Google Scholar
• DavidsonMHArmaniAMcKenneyJMJacobsonTASafety considerations with fibrate therapyAm J Cardiol2007993C18C
   PubMed Web of Science ®Google Scholar
• TutejaSPyrsopoulosNTWolowichWRSimvastatin-ezetimibe- induced hepatic failure necessitating liver transplantationPharmacotherapy2008281188119318752389
   PubMed Web of Science ®Google Scholar
• CastelloteJArizaJRotaRGirbauAXiolXSerious drug-induced liver disease secondary to ezetimibeWorld J Gastroenterol2008145098509918763297
   PubMed Web of Science ®Google Scholar
• StolkMFJBecxMCJMKuypersKCSeldenrijkCASevere hepatic side effects of ezetimibeClin Gastroenterol Hepatol2006490891116797241
   PubMed Web of Science ®Google Scholar
• BrownWVSafety of statinsCurr Opin Lipidol20081955856218957877
   PubMed Web of Science ®Google Scholar
• KashaniASallamTBheemreddySMannDLWangYFoodyJMReview of side-effect profile of combination ezetimibe and statin therapy in randomized clinical trialsAm J Cardiol20081011606161318489938
   PubMed Web of Science ®Google Scholar
• KaganAMcGeeDLYanoKRhoadsGGNomuraASerum cholesterol and mortality in a Japanese-American population: the Honolulu Heart programAm J Epidemiol198111411207246518
   PubMed Web of Science ®Google Scholar
• DuncanREEl-SohemyAArcherMCStatins and cancer developmentCancer Epidemiol Biomarkers Prev2005141897189816103434
   PubMed Web of Science ®Google Scholar
• BoudreauDMYuOJohnsonJStatin use and cancer risk: a comprehensive reviewExpert Opin Drug Saf2010960362120377474
   PubMed Web of Science ®Google Scholar
• ShepherdJBlauwGJMurphyMBPravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trialLancet20023601623163012457784
   PubMed Web of Science ®Google Scholar
• RossebøABPedersenTRBomanKIntensive lipid lowering with simvastatin and ezetimibe in aortic stenosisN Engl J Med20083591343135618765433
   PubMed Web of Science ®Google Scholar
• PetoREmbersonJLandrayMAnalyses of cancer data from three ezetimibe trialsN Engl J Med20083591357136618765432
   PubMed Web of Science ®Google Scholar
• HowardBVRomanMJDevereuxRBEffect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trialJAMA20082991678168918398080
   PubMed Web of Science ®Google Scholar
• TaylorAJVillinesTCStanekEJExtended-release niacin or ezetimibe and carotid intima-media thicknessN Engl J Med20093612113212219915217
   PubMed Web of Science ®Google Scholar
• SteinEAAdditional lipid lowering trials using surrogate measurements of atherosclerosis by carotid intima-media thickness: more clarity or confusion?J Am Coll Cardiol2008522206220919095140
   PubMed Web of Science ®Google Scholar
• SmildeTJvan WissenSWollersheimHTripMDKasteleinJJStalenhoefAFEffect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trialLancet200135757758111558482
   PubMed Web of Science ®Google Scholar
• TothPPMakiKCA Commentary on the implications of the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) Trial: Should ezetimibe move to the ‘Back of the Line’ as a therapy for dyslipidemia?J Clin Lipidol2008231331721291755
   PubMed Web of Science ®Google Scholar
• SimonTBoutouyriePGompelARationale, design and methods of the CASHMERE studyFundam Clin Pharmacol20041813113814748765
   PubMed Web of Science ®Google Scholar
• FlegJLMeteMHowardBVEffect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trialJ Am Coll Cardiol2008522198220519095139
   PubMed Web of Science ®Google Scholar
• MeaneyACeballosGAsbunJThe VYtorin on Carotid intimamedia thickness and overall arterial rigidity (VYCTOR) studyJ Clin Pharmacol20094983884719443679
   PubMed Web of Science ®Google Scholar
• BlumenthalRSMichosEDThe HALTS trial – halting atherosclerosis or halted too early?N Engl J Med20093612178218019915216
   PubMed Web of Science ®Google Scholar
• KasteleinJJPBotsMLStatin therapy with ezetimibe or niacin in high-risk patientsN Engl J Med20093612180218319915218
   PubMed Web of Science ®Google Scholar
• HolmeIBomanKBrudiPObserved and predicted reduction of ischemic cardiovascular events in the Simvastatin and Ezetimibe in Aortic Stenosis TrialAm J Cardiol20101051802180820538134
   PubMed Web of Science ®Google Scholar
• FellströmBCJardineAGSchmiederRERosuvastatin and cardiovascular events in patients undergoing hemodialysisN Engl J Med20093601395140719332456
   PubMed Web of Science ®Google Scholar
• WannerCKraneVMärzWAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysisN Engl J Med200535323824816034009
   PubMed Web of Science ®Google Scholar
• ScarpioniRRicardiMMelfaLCristinelliLDyslipidemia in chronic kidney disease: are statins still indicated in reduction cardiovascular risk in patients on dialysis treatment?Cardiovasc Ther20102836136820553296
   PubMed Web of Science ®Google Scholar
• CannonCPGiuglianoRPBlazingMARationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromesAm Heart J200815682683219061694
   PubMed Web of Science ®Google Scholar
• CaliffRMLokhnyginaYCannonCPAn update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) designAm Heart J201015970570920435175
   PubMed Web of Science ®Google Scholar